Search Results

Iovance Biotherapeutics, Inc. announced that on June 20, 2024, the Company approved the grant of inducement stock options covering an aggregate of 187,650 shares of Iovance’s common stock to forty-three new, non-executive employees.

Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, announced that senior leadership plans to present at the following conferences and events.

Iovance Biotherapeutics, Inc. submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for lifileucel, a TIL cell therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.

Iovance Biotherapeutics, Inc. announced that on May 16, 2024, the Company approved the grant of inducement stock options covering an aggregate of 153,930 shares of Iovance’s common stock to thirty new, non-executive employees.

Iovance Biotherapeutics, Inc., a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, announced that senior leadership plans to present at the following conferences.

Iovance Biotherapeutics, Inc., a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, reported first quarter 2024 financial results and corporate updates.

Iovance Biotherapeutics, Inc. announced updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting to be held May 31 – June 4, 2024, at McCormick Place in Chicago, IL and online.

Iovance Biotherapeutics, Inc. announced that on April 18, 2024, the Company approved the grant of inducement stock options covering an aggregate of 79,310 shares of Iovance’s common stock to thirty-seven new, non-executive employees.

Iovance Biotherapeutics, Inc. announced the pricing of an underwritten offering of 23,014,000 shares of its common stock at an offering price of $9.15 per share.

Iovance Biotherapeutics, Inc. announced that clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, will be highlighted at the upcoming 2024 ASCO Annual Meeting to be held May 31- June 4, 2024, at McCormick Place in Chicago, IL and online.